Domain Therapeutics SA, of Strasbourg, France, and Xoma Corp., of Berkeley, Calif., entered a multistep collaboration involving Xoma’s research on allosteric modulation and Domain’s Dtect-All, a platform that has discovered small-molecule allosteric modulators for a wide range of G protein-coupled receptors (GPCRs).